These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24479751)

  • 1. L-/N-type calcium channel blockers and proteinuria.
    Ando K
    Curr Hypertens Rev; 2013 Aug; 9(3):210-8. PubMed ID: 24479751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
    Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
    Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-type Ca channel blockers in patients with chronic kidney disease in clinical practice.
    Abe M; Okada K; Soma M
    Curr Hypertens Rev; 2013 Aug; 9(3):202-9. PubMed ID: 24479749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
    Fujita T; Ando K; Nishimura H; Ideura T; Yasuda G; Isshiki M; Takahashi K;
    Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Ando K; Ueshima K; Tanaka S; Kosugi S; Sato T; Matsuoka H; Nakao K; Fujita T
    Int J Med Sci; 2013; 10(9):1209-16. PubMed ID: 23935398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats.
    Konda T; Enomoto A; Takahara A; Yamamoto H
    Biol Pharm Bull; 2006 May; 29(5):933-7. PubMed ID: 16651722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.
    Naseratun N; Kobara M; Watanabe Y; Toba H; Nakata T
    Clin Exp Pharmacol Physiol; 2020 Sep; 47(9):1545-1553. PubMed ID: 32323339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Matsuoka H; Ando K; Ueshima K; Babazono T; Kario K; Tanaka S; Nakao K; Fujita T;
    Clin Exp Hypertens; 2011; 33(7):455-62. PubMed ID: 21649534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
    Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
    Ohishi M; Takagi T; Ito N; Terai M; Tatara Y; Hayashi N; Shiota A; Katsuya T; Rakugi H; Ogihara T
    Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis.
    Thamcharoen N; Susantitaphong P; Wongrakpanich S; Chongsathidkiet P; Tantrachoti P; Pitukweerakul S; Avihingsanon Y; Praditpornsilpa K; Jaber BL; Eiam-Ong S
    Hypertens Res; 2015 Dec; 38(12):847-55. PubMed ID: 26134125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
    Aritomi S; Koganei H; Wagatsuma H; Mitsui A; Ogawa T; Nitta K; Konda T
    Heart Vessels; 2010 Nov; 25(6):549-55. PubMed ID: 20922532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.
    Aritomi S; Konda T; Yoshimura M
    Heart Vessels; 2012 Jul; 27(4):419-23. PubMed ID: 21989861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
    Moore KH; Clemmer JS
    Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
    Fan YY; Kohno M; Nakano D; Ohsaki H; Kobori H; Suwarni D; Ohashi N; Hitomi H; Asanuma K; Noma T; Tomino Y; Fujita T; Nishiyama A
    J Hypertens; 2010 May; 28(5):1034-43. PubMed ID: 20411599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.